Testicular cancer
Testicular cancer is a malignant tumor that occurs in the testicles of the male reproductive system. It is a common tumor in the male reproductive system, accounting for about 2% of male malignant tumors. Testicular cancer is more common in young men aged 20 to 40. As one of the most common cancers in young men, the cause of testicular cancer is not well known. According to statistics, the incidence of testicular cancer in men is 7 in 100,000, and it is increasing year by year. The cause is usually caused by the metastasis of malignant tumors.
-
Site of disease:
testis -
Infectious :
Not contagious -
Frequent population:
Adult male -
Related symptoms:
Testicular pain testicular enlargement and hardening scrotal prolapse scrotal swelling
Related Drugs
Cisplatin Injection
Indication: Used for various sarcomas such as nasopharyngeal carcinoma, ovarian cancer, bladder cancer, testicular cancer, lymphosarcoma, reticular cell sarcoma, etc.
Manufacturer:
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Cisplatin Injection
Indication: Used for various sarcomas such as nasopharyngeal carcinoma, ovarian cancer, bladder cancer, testicular cancer, lymphosarcoma, reticular cell sarcoma, etc.
Ifosfamide for injection
Indication: Suitable for testicular cancer, ovarian cancer, breast cancer, sarcoma, malignant lymphoma and lung cancer, etc.
Manufacturer:
Hainan Zhuotai Pharmaceutical Co., Ltd.
Ifosfamide for injection
Indication: Suitable for testicular cancer, ovarian cancer, breast cancer, sarcoma, malignant lymphoma and lung cancer, etc.
Ifosfamide for injection
Indication: Suitable for testicular cancer, ovarian cancer, breast cancer, sarcoma, malignant lymphoma and lung cancer, etc.
Manufacturer:
Shijiazhuang Kaida Bioengineering Co., Ltd.
Ifosfamide for injection
Indication: Suitable for testicular cancer, ovarian cancer, breast cancer, sarcoma, malignant lymphoma and lung cancer, etc.
Manufacturer:
Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd.
Carboplatin Injection
Indication: It is mainly used for patients with advanced ovarian cancer, testicular cancer, head and neck cancer, lung cancer, etc. who cannot tolerate vomiting caused by cisplatin treatment.
Manufacturer:
Qilu Pharmaceutical Co., Ltd.
Actinomycin D for injection
Indication: 1. It has outstanding efficacy in the treatment of Hodgkin's disease (HD) and neuroblastoma, especially in controlling fever. 2. The cure rate of this drug alone for the initial treatment of non-metastatic choriocarcinoma is 90% to 100%, which is similar to the effect of MTX alone. 3. It is also effective for testicular cancer and is generally used in combination with other drugs. 4. Combining it with radiotherapy to treat childhood Wilms tumor can improve the survival rate, and it is also effective for Ewing sarcoma and rhabdomyosarcoma.
Manufacturer:
Shanghai SPH New ASIA Pharmaceutical Co., Ltd.
Actinomycin D for injection
Indication: 1. It has outstanding efficacy in the treatment of Hodgkin's disease (HD) and neuroblastoma, especially in controlling fever. 2. The cure rate of this drug alone for the initial treatment of non-metastatic choriocarcinoma is 90% to 100%, which is similar to the effect of MTX alone. 3. It is also effective for testicular cancer, and is generally used in combination with other drugs. 4. Combining it with radiotherapy to treat childhood Wilms tumor can improve the survival rate, and it is also effective for Ewing sarcoma and rhabdomyosarcoma.
Manufacturer:
Han Hui Pharmaceuticals Company Limited
Cisplatin for injection
Indication: It is the first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is the first-line treatment for SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is currently a commonly used regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. PVB (DDP, VLB, BLM) can treat most stage IV non-spermogenic testicular cancers with a remission rate of 50% to 80%. In addition, this product is a radiotherapy sensitizer. It is currently widely used abroad for local radiotherapy of stage IV inoperable NSCLC, which can provide
Manufacturer:
Qilu Pharmaceutical Co., Ltd.
Related Ingredients